Lesley A. Mathews Griner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lesley A. Mathews Griner has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Astin S. Powers
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
45 shared publications - Humair S. Quadri
Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
45 shared publications - Udo Rudloff
Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
45 shared publications - Anne M. Miermont
Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
44 shared publications - Dandan Li
Rare Tumor Initiative, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
44 shared publications - Marc Ferrer
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland
44 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Secondary validation of candidate genes.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Secondary validation of candidate genes.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Lists of cell lines, antibodies, RNAi kinome screen; and matrix drug combination.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Lists of cell lines, antibodies, RNAi kinome screen; and matrix drug combination.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Schematic layout of the selumetinib versus 26 compounds targeting effector signaling of CNKSR1 screen; and Dose response of MK-2206 and rapamycin in the pancreas cancer cell lines.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Schematic layout of the selumetinib versus 26 compounds targeting effector signaling of CNKSR1 screen; and Dose response of MK-2206 and rapamycin in the pancreas cancer cell lines.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
CNKSR1 promotes MEK inhibition-induced AKT activation.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
CNKSR1 promotes MEK inhibition-induced AKT activation.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
MEK blockade fails to disrupt protein-protein interactions of CNKSR1, KSR1/2, and MEK in CNKSR1low cancer cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
MEK blockade fails to disrupt protein-protein interactions of CNKSR1, KSR1/2, and MEK in CNKSR1low cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Selumetinib fails to recruit CNKSR1 and p-AKT to the plasma membrane in CNKSR1 low cell lines; Proximal ligation of CNKSR1 and p-AKT in CNKSR1 low cell lines treated with vehicle vs selumetinib;CNKSR1 p-AKT PLA signal after treatment with selumetinib is dependent on the presence of both primary antibodies; Silencing of CNKSR1 in the CNKSR1high cell lines abrogates PLA signal; and Immunofluorescence staining of PIP3 and CNKSR1 in YAPC treated with vehicle and selumetinib.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Selumetinib fails to recruit CNKSR1 and p-AKT to the plasma membrane in CNKSR1 low cell lines; Proximal ligation of CNKSR1 and p-AKT in CNKSR1 low cell lines treated with vehicle vs selumetinib;CNKSR1 p-AKT PLA signal after treatment with selumetinib is dependent on the presence of both primary antibodies; Silencing of CNKSR1 in the CNKSR1high cell lines abrogates PLA signal; and Immunofluorescence staining of PIP3 and CNKSR1 in YAPC treated with vehicle and selumetinib.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.